 The study will evaluate the safety and tolerability of repeated intratumoral administrations of TBI-1401HF10 at dose levels of 1 x 106 TCID50dose cohort 1 and 1 x 107 TCID50dose cohort 2 in Japanese patients. Three patients will be enrolled in each cohort. Patients in the each cohort will receive a total of four intratumoral administrations in the same lesion. 